Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Short Interest Down 71.7% in January

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) was the target of a significant drop in short interest in the month of January. As of January 15th, there was short interest totaling 16,265 shares, a drop of 71.7% from the December 31st total of 57,446 shares. Based on an average daily volume of 106,459 shares, the short-interest ratio is currently 0.2 days. Currently, 0.9% of the shares of the company are sold short. Currently, 0.9% of the shares of the company are sold short. Based on an average daily volume of 106,459 shares, the short-interest ratio is currently 0.2 days.

Bluejay Diagnostics Trading Down 3.8%

Shares of NASDAQ BJDX opened at $0.76 on Wednesday. The firm has a market cap of $1.38 million, a P/E ratio of -0.01 and a beta of 0.65. The business’s 50 day moving average is $0.92 and its 200-day moving average is $1.45. Bluejay Diagnostics has a 1-year low of $0.63 and a 1-year high of $10.20.

Shares of Bluejay Diagnostics are set to reverse split on the morning of Thursday, January 29th. The 1-4 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Wednesday, January 28th.

Bluejay Diagnostics (NASDAQ:BJDX) last released its quarterly earnings results on Friday, November 7th. The company reported ($1.01) EPS for the quarter.

Analyst Ratings Changes

A number of analysts have recently issued reports on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bluejay Diagnostics in a research report on Monday, December 29th. Wall Street Zen raised Bluejay Diagnostics to a “sell” rating in a report on Saturday, November 1st. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has an average rating of “Sell”.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.